Madam Speaker, the whole issue around pharmacoeconomics is very complex because governments look at the potential benefits of drug use versus the costs, and it becomes a budgetary and political decision. What we are doing with pharmacare is providing more funding so we can surmount these political and budgetary obstacles to providing Canadians with the drugs they need for free.
In the House of Commons on April 16th, 2024. See this statement in context.